Adult and juvenile dermatomyositis treatment

被引:5
作者
Patil, Anant [1 ]
Lu, Jun [2 ]
Kassir, Martin [3 ]
Babaei, Mahsa [4 ]
Goldust, Mohamad [5 ]
机构
[1] Dr DY Patil Med Coll, Dept Pharmacol, Navi Mumbai, India
[2] UConn Hlth Dept Dermatol, Farmington, CT USA
[3] Worldwide Laser Inst, Dallas, TX USA
[4] Shahid Beheshti Univ Med Sci, Tehran, Iran
[5] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Mainz, Germany
关键词
corticosteroids; dermatomyositis; immunosuppressants; malignancy; management; REFRACTORY ADULT; POLYMYOSITIS; RITUXIMAB;
D O I
10.1111/jocd.15363
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction Dermatomyositis is a rare autoimmune inflammatory condition affecting skin and muscles. The disease can be seen in both adults and children. It can be associated with malignancy. Considering involvement of skin in the disease, many patients consult dermatologists for its treatment. Hence, knowledge about its presentation, complications, prognosis, and treatment is necessary. Objective The objective of this review article is to provide comprehensive information about treatment of dermatomyositis. Methods In this review article, we reviewed the published literature on adult and juvenile dermatomyositis to highlight the treatment. Articles published in peer-reviewed journals including reviews, clinical trials, case series, and case reports published in electronic database (MEDLINE/PubMed) through January 2021, cross references of respective articles and trials from were included for qualitative analysis of the literature. Results Treatment options for dermatomyositis include traditional immunosuppressive agents and immunomodulatory therapy. High-dose corticosteroids represent the first line of treatment while other immunosuppressive agents are also used, either in combination with or as an alternative to corticosteroids, after initial treatment failure. Some biological agents have been used for the treatment of dermatomyositis with variable responses. Conclusion Although several treatment options are available, several questions remain unanswered about the optimal treatment of dermatomyositis.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 50 条
  • [31] JUVENILE DERMATOMYOSITIS
    Faller, Gail
    CURRENT ALLERGY & CLINICAL IMMUNOLOGY, 2010, 23 (03) : 111 - 114
  • [32] Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis
    Sparling, A. Clare
    Ward, James M.
    Sarkar, Kakali
    Schiffenbauer, Adam
    Farhadi, Payam Noroozi
    Smith, Michael A.
    Rahman, Saifur
    Zerrouki, Kamelia
    Miller, Frederick W.
    Li, Jian-Liang
    Casey, Kerry A.
    Rider, Lisa G.
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [33] Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
    Campanilho-Marques, Raquel
    Deakin, Claire T.
    Simou, Stefania
    Papadopoulou, Charalampia
    Wedderburn, Lucy R.
    Pilkington, Clarissa A.
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [34] Juvenile dermatomyositis: new insights and new treatment strategies
    Martin, Neil
    Li, Charles K.
    Wedderburn, Lucy R.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2012, 4 (01) : 41 - 50
  • [35] Biologic drugs in the treatment of juvenile dermatomyositis: a literature review
    Seher Sener
    Veysel Cam
    Seza Ozen
    Ezgi Deniz Batu
    Clinical Rheumatology, 2024, 43 : 591 - 602
  • [36] Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances
    Rocha, Aline Maria de Oliveira
    Ribeiro, Gabriel Fidelis
    Silva, Juliana Capecce
    REUMATOLOGIA, 2024, 62 (06): : 447 - 455
  • [37] Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis
    Oliveri, MB
    Palermo, R
    Mautalen, C
    Hubscher, O
    JOURNAL OF RHEUMATOLOGY, 1996, 23 (12) : 2152 - 2155
  • [38] Patient reported physical function, mental health, and treatment patterns in dermatomyositis: survey results from a cross-sectional study of adult dermatomyositis patients
    Christopher-Stine, Lisa
    Paik, Julie J.
    Goriounova, Alexandra S.
    Mudd Jr, Paul N.
    BMC RHEUMATOLOGY, 2025, 9 (01)
  • [39] Update on the clinical management of juvenile dermatomyositis
    Huber, Adam M.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (12) : 1021 - 1028
  • [40] Juvenile Dermatomyositis as a Paraneoplastic Phenomenon: An Update
    Morris, Paula
    Dare, Jason
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (03) : 189 - 191